--- title: "Appetite Regulation Peptides | PepTracker Pro" description: "Peptides that influence hunger signaling and satiety pathways." lang: en json-ld: --- [Skip to main content](#main) **Educational information only.** This site does not provide medical advice. [Read full disclaimer](/disclaimer) [PepTracker Pro](/) [Home](/)[Peptides](/peptides)[Compare](/compare)[Glossary](/glossary)[Blog](/blog)[Calculators](/calculators)[Start Here](/start) [Open the App](https://app.peptrackerpro.com) [Peptides](/peptides)/ Appetite Regulation # Appetite Regulation Peptides Peptides that influence hunger signaling and satiety pathways. ### Aleniglipron Medium Evidence An oral non-peptide small-molecule GLP-1 receptor agonist achieving 16.3% placebo-adjusted weight loss at 44 weeks in Phase 2 ACCESS II, with Phase 3 on track for Q3 2026 after positive FDA end-of-Phase 2 feedback. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/aleniglipron) [\+ Compare](/compare?select=aleniglipron)[](https://app.peptrackerpro.com/?add=aleniglipron) ### Amycretin Medium Evidence A unimolecular GLP-1 and amylin receptor dual agonist in Phase 3 trials, available in both subcutaneous and oral formulations, with up to 22% weight loss in Phase 1b/2a. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)+1 more [View Details](/peptides/amycretin) [\+ Compare](/compare?select=amycretin)[](https://app.peptrackerpro.com/?add=amycretin) ### ASC30 Low Evidence An oral once-daily small-molecule GLP-1 receptor agonist developed by Ascletis Pharma, showing 5.4–7.7% placebo-adjusted weight loss at 13 weeks in Phase 2, with in vitro potency 2–3x greater than orforglipron. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/asc30) [\+ Compare](/compare?select=asc30)[](https://app.peptrackerpro.com/?add=asc30) ### ASC35 Low Evidence A next-generation once-monthly GLP-1R/GIPR dual agonist peptide with a 14-day half-life (6-fold longer than tirzepatide) and 71% greater weight loss than tirzepatide in preclinical models. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/asc35) [\+ Compare](/compare?select=asc35)[](https://app.peptrackerpro.com/?add=asc35) ### ASC36 Low Evidence A next-generation once-monthly amylin receptor agonist peptide with a 32-day half-life and 91% greater weight loss than petrelintide in preclinical models. IND filing expected Q2 2026. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/asc36) [\+ Compare](/compare?select=asc36)[](https://app.peptrackerpro.com/?add=asc36) ### ASC37 Low Evidence A next-generation once-monthly GLP-1R/GIPR/GCGR triple peptide agonist with 5-fold greater potency than retatrutide and a 17-day half-life enabling monthly dosing. IND filing expected Q2 2026. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/asc37) [\+ Compare](/compare?select=asc37)[](https://app.peptrackerpro.com/?add=asc37) ### Berobenatide Medium Evidence A once-monthly injectable GLP-1 receptor agonist developed by Pfizer (acquired from Metsera), showing 12.3% placebo-adjusted weight loss in Phase 2b trials with a tolerability profile comparable to weekly semaglutide. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/berobenatide) [\+ Compare](/compare?select=berobenatide)[](https://app.peptrackerpro.com/?add=berobenatide) ### BI 3034701 Low Evidence A potential first-in-class triple GLP-1, GIP, and NPY2 receptor agonist peptide entering Phase 2 development mid-2026 for obesity, developed by Boehringer Ingelheim using Gubra-discovered technology. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism) [View Details](/peptides/bi-3034701) [\+ Compare](/compare?select=bi-3034701)[](https://app.peptrackerpro.com/?add=bi-3034701) ### BRP Low Evidence A 12-amino-acid peptide discovered via AI that suppresses appetite by acting on the hypothalamus, without nausea or muscle loss observed in animal models. [Appetite Regulation](/benefits/appetite-regulation)[Weight Management](/benefits/weight-management)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism) [View Details](/peptides/brp) [\+ Compare](/compare?select=brp)[](https://app.peptrackerpro.com/?add=brp) ### BWB3054 Low Evidence A GIP/glucagon dual agonist that achieves weight loss comparable to retatrutide without GLP-1 receptor activity, potentially eliminating GI side effects. Published in Molecular Metabolism (April 2026). [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/bwb3054) [\+ Compare](/compare?select=bwb3054)[](https://app.peptrackerpro.com/?add=bwb3054) ### Cagrilintide High Evidence A long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism) [View Details](/peptides/cagrilintide) [\+ Compare](/compare?select=cagrilintide)[](https://app.peptrackerpro.com/?add=cagrilintide) ### CagriSema High Evidence A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) studied for enhanced weight loss through dual hormonal pathways. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism) [View Details](/peptides/cagrisema) [\+ Compare](/compare?select=cagrisema)[](https://app.peptrackerpro.com/?add=cagrisema) ### CAP-GDF15 Low Evidence A newly discovered 12-amino acid anorexigenic peptide derived from the GDF15 prepropeptide region, representing a novel appetite-suppression pathway. [Appetite Regulation](/benefits/appetite-regulation)[Weight Management](/benefits/weight-management)[Metabolism](/benefits/metabolism) [View Details](/peptides/cap-gdf15) [\+ Compare](/compare?select=cap-gdf15)[](https://app.peptrackerpro.com/?add=cap-gdf15) ### Cotadutide Medium Evidence A once-daily GLP-1/glucagon dual receptor agonist studied for MASH, obesity, and type 2 diabetes with demonstrated liver fat reduction and antifibrotic activity. [Weight Management](/benefits/weight-management)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)[Appetite Regulation](/benefits/appetite-regulation) [View Details](/peptides/cotadutide) [\+ Compare](/compare?select=cotadutide)[](https://app.peptrackerpro.com/?add=cotadutide) ### CX11 Medium Evidence CX11 is an investigational once-daily oral small-molecule GLP-1 receptor agonist (Corxel/Vincentage) that produced up to 11.5% weight loss at 36 weeks in a 246-patient U.S. Phase 2 obesity trial, with a notably low 12-16% vomiting rate and no hepatic safety signal; global Phase 3 is planned after positive China Phase 3 results. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)+1 more [View Details](/peptides/cx11) [\+ Compare](/compare?select=cx11)[](https://app.peptrackerpro.com/?add=cx11) ### DA-1726 Low Evidence A novel once-weekly GLP-1/glucagon dual receptor agonist showing rapid weight loss in Phase 1 trials with preserved lean body mass and direct liver benefits. [Weight Management](/benefits/weight-management)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism)[Appetite Regulation](/benefits/appetite-regulation) [View Details](/peptides/da-1726) [\+ Compare](/compare?select=da-1726)[](https://app.peptrackerpro.com/?add=da-1726) ### Danuglipron Medium Evidence An oral small-molecule GLP-1 receptor agonist discontinued by Pfizer in 2026 after a potential drug-induced liver injury signal, despite showing meaningful weight loss in Phase 2b. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism) [View Details](/peptides/danuglipron) [\+ Compare](/compare?select=danuglipron)[](https://app.peptrackerpro.com/?add=danuglipron) ### Ecnoglutide High Evidence A cAMP signaling-biased GLP-1 receptor agonist approved in China for chronic weight management, with Phase 3 data showing up to 15.4% weight loss. [Weight Management](/benefits/weight-management)[Fat Loss](/benefits/fat-loss)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism) [View Details](/peptides/ecnoglutide) [\+ Compare](/compare?select=ecnoglutide)[](https://app.peptrackerpro.com/?add=ecnoglutide) ### Eloralintide Medium Evidence A selective, long-acting amylin receptor agonist in Phase 3 trials for obesity, offering a GLP-1-independent weight loss mechanism with up to 20.1% weight loss in Phase 2. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/eloralintide) [\+ Compare](/compare?select=eloralintide)[](https://app.peptrackerpro.com/?add=eloralintide) ### GDF-15 Receptor Agonists Medium Evidence A new class of peptide-based weight loss therapeutics that act through the GFRAL/RET receptor in the brainstem, representing a non-GLP-1 mechanism for appetite suppression and energy expenditure regulation. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism)+1 more [View Details](/peptides/gdf15-agonists) [\+ Compare](/compare?select=gdf15-agonists)[](https://app.peptrackerpro.com/?add=gdf15-agonists) ### GEP-44 Low Evidence A novel triple agonist peptide targeting GLP-1 and peptide YY receptors Y1 and Y2, designed to suppress appetite and improve glycemic control while avoiding GI side effects common to first-generation GLP-1 drugs. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism) [View Details](/peptides/gep-44) [\+ Compare](/compare?select=gep-44)[](https://app.peptrackerpro.com/?add=gep-44) ### GHRP-6 Medium Evidence A growth hormone secretagogue that also stimulates appetite through ghrelin receptor activation. [Muscle Growth](/benefits/muscle-growth)[Fat Loss](/benefits/fat-loss)[Recovery](/benefits/recovery)[Appetite Regulation](/benefits/appetite-regulation) [View Details](/peptides/ghrp-6) [\+ Compare](/compare?select=ghrp-6)[](https://app.peptrackerpro.com/?add=ghrp-6) ### GLP-1-GIP-Lani (Quintuple Agonist) Low Evidence A first-in-class peptide-drug conjugate that simultaneously activates five metabolic receptors (GLP-1R, GIPR, PPARα, PPARγ, PPARδ), published in Nature in April 2026 with preclinical results surpassing tirzepatide and triple agonists. [Weight Management](/benefits/weight-management)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism)[Appetite Regulation](/benefits/appetite-regulation) [View Details](/peptides/glp1-gip-lani) [\+ Compare](/compare?select=glp1-gip-lani)[](https://app.peptrackerpro.com/?add=glp1-gip-lani) ### KAI-7535 Medium Evidence An oral once-daily small-molecule GLP-1 receptor agonist (Hengrui's HRS-7535, licensed to Kailera) that delivered up to 10.9% weight loss at Week 44 in a Chinese Phase 3 obesity trial and met its Phase 3 diabetes endpoint, now in a global Phase 2 dose-optimization study. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[blood-sugar-control](/benefits/blood-sugar-control)+1 more [View Details](/peptides/kai-7535) [\+ Compare](/compare?select=kai-7535)[](https://app.peptrackerpro.com/?add=kai-7535) ### Maridebart Cafraglutide (MariTide) Medium Evidence Amgen's once-monthly injectable GIP receptor antagonist and GLP-1 receptor agonist, showing up to 20% weight loss in phase 2 trials with a unique mechanism that blocks GIP while activating GLP-1. [Weight Management](/benefits/weight-management)[Metabolism](/benefits/metabolism)[Appetite Regulation](/benefits/appetite-regulation)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/maridebart-cafraglutide) [\+ Compare](/compare?select=maridebart-cafraglutide)[](https://app.peptrackerpro.com/?add=maridebart-cafraglutide) ### MariTide High Evidence A bispecific GIPR antagonist and GLP-1 receptor agonist antibody-peptide conjugate developed by Amgen for obesity and type 2 diabetes. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism) [View Details](/peptides/maritide) [\+ Compare](/compare?select=maritide)[](https://app.peptrackerpro.com/?add=maritide) ### Mazdutide High Evidence The first dual GCG/GLP-1 receptor agonist approved in China for obesity and T2D, with Phase 3 showing up to 20.1% weight loss at the 9 mg dose and superiority over semaglutide. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism) [View Details](/peptides/mazdutide) [\+ Compare](/compare?select=mazdutide)[](https://app.peptrackerpro.com/?add=mazdutide) ### MBX 4291 Low Evidence A GLP-1/GIP co-agonist prodrug engineered for once-monthly dosing using MBX Biosciences' PEP platform. Phase 1 blinded data showed 7% mean weight loss at 8 weeks with minimal GI side effects. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism) [View Details](/peptides/mbx-4291) [\+ Compare](/compare?select=mbx-4291)[](https://app.peptrackerpro.com/?add=mbx-4291) ### MBX 5765 Low Evidence A novel quadruple agonist prodrug combining GLP-1, GIP, glucagon, and DACRA (dual amylin and calcitonin receptor agonist) activity in a single molecule, designed for once-monthly dosing and superior efficacy. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism) [View Details](/peptides/mbx-5765) [\+ Compare](/compare?select=mbx-5765)[](https://app.peptrackerpro.com/?add=mbx-5765) ### NA-931 (Bioglutide) Medium Evidence The first oral quadruple receptor agonist targeting IGF-1, GLP-1, GIP, and glucagon receptors for obesity treatment with muscle preservation. [Weight Management](/benefits/weight-management)[Fat Loss](/benefits/fat-loss)[muscle-preservation](/benefits/muscle-preservation)[Metabolism](/benefits/metabolism)+1 more [View Details](/peptides/na-931) [\+ Compare](/compare?select=na-931)[](https://app.peptrackerpro.com/?add=na-931) ### Orforglipron High Evidence The first oral non-peptide GLP-1 receptor agonist, FDA-approved in April 2026 for chronic weight management with no food or water restrictions. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)+1 more [View Details](/peptides/orforglipron) [\+ Compare](/compare?select=orforglipron)[](https://app.peptrackerpro.com/?add=orforglipron) ### PF-08653944 Medium Evidence An ultra-long-acting injectable GLP-1 receptor agonist enabling monthly dosing, with 12.3% placebo-adjusted weight loss in Phase 2b and 10 Phase 3 trials planned. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism) [View Details](/peptides/pf-08653944) [\+ Compare](/compare?select=pf-08653944)[](https://app.peptrackerpro.com/?add=pf-08653944) ### Retatrutide High Evidence An investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/retatrutide) [\+ Compare](/compare?select=retatrutide)[](https://app.peptrackerpro.com/?add=retatrutide) ### Ribupatide Medium Evidence A once-weekly injectable GLP-1/GIP dual receptor agonist in Phase 3 trials for obesity, with an oral formulation in development and backed by a record-setting $625M biotech IPO. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/ribupatide) [\+ Compare](/compare?select=ribupatide)[](https://app.peptrackerpro.com/?add=ribupatide) ### Semaglutide High Evidence A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)+3 more [View Details](/peptides/semaglutide) [\+ Compare](/compare?select=semaglutide)[](https://app.peptrackerpro.com/?add=semaglutide) ### Survodutide Medium Evidence A dual GLP-1/glucagon receptor agonist with FDA Breakthrough Therapy designation for MASH and Priority Review NDA filed February 2026. Phase 3 SYNCHRONIZE-1 reported 16.6% weight loss at 76 weeks; approval possible Q3 2026. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/survodutide) [\+ Compare](/compare?select=survodutide)[](https://app.peptrackerpro.com/?add=survodutide) ### Tirzepatide High Evidence A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)+1 more [View Details](/peptides/tirzepatide) [\+ Compare](/compare?select=tirzepatide)[](https://app.peptrackerpro.com/?add=tirzepatide) ### UBT251 Medium Evidence A GLP-1/GIP/glucagon triple receptor agonist in Phase 2 development for type 2 diabetes and obesity, competing with retatrutide in the triple-agonist space. [Weight Management](/benefits/weight-management)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism)[Appetite Regulation](/benefits/appetite-regulation) [View Details](/peptides/ubt251) [\+ Compare](/compare?select=ubt251)[](https://app.peptrackerpro.com/?add=ubt251) ### VK2735 Medium Evidence An investigational oral and injectable GLP-1/GIP dual agonist showing 12.2% oral weight loss at 13 weeks at ECO 2026 and 14.7% injectable weight loss, with Phase 3 VANQUISH trials fully enrolled. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/vk2735) [\+ Compare](/compare?select=vk2735)[](https://app.peptrackerpro.com/?add=vk2735) ### Zenagamtide Low Evidence A unimolecular GLP-1 and amylin receptor co-agonist developed by Novo Nordisk, available in both subcutaneous and oral formulations, with Phase 2 data showing up to 24.3% weight loss and Phase 3 AMAZE trials initiated in 2026. [weight-loss](/benefits/weight-loss)[metabolic-health](/benefits/metabolic-health)[type-2-diabetes](/benefits/type-2-diabetes)[obesity](/benefits/obesity)+1 more [View Details](/peptides/zenagamtide) [\+ Compare](/compare?select=zenagamtide)[](https://app.peptrackerpro.com/?add=zenagamtide) Track Your Research with PepTracker Pro [Try the Free App →](https://app.peptrackerpro.com) [PepTracker Pro](/) Educational peptide information and research tracking tools. Not medical advice. #### Explore - [Peptide Directory](/peptides) - [Compare Peptides](/compare) - [Glossary](/glossary) - [Benefits](/benefits/sleep) #### Learn - [Blog](/blog) - [Calculators](/calculators) - [Start Here](/start) - [About](/about) #### Legal - [Editorial Policy](/editorial-policy) - [Research Disclaimer](/research-disclaimer) - [Disclaimer](/disclaimer) - [Privacy Policy](/privacy) - [Terms of Service](/terms) - [Contact](/contact) © 2026 PepTracker Pro. Educational purposes only. Not medical advice. Always consult a licensed healthcare provider.